Georgy Z. Chkadua
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Georgy Z. Chkadua has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Igor Stanislavovich Dolgopolov
Children’s Regional Clinical Hospital; Tver State Medical University
3 shared publications - Dmitry A. Buletov
Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина Минздрава России
1 shared publication G.L. Mentkevich
1 shared publication- Maksim Yu. Rykov
Russian State Social University
1 shared publication - Marina Vladimirovna Ryzhova
N.N. Burdenko National Medical Research Center of Neurosurgery, Ministry of Health of Russia
1 shared publication - Nikolay Aleksandrovich Kozlov
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
1 shared publication
Latest Publications
- 1 January 2022
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 11 (6)
Immunotherapy for a patient with high-grade glioblastoma
- 1 January 2022
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 11 (6)
Immunotherapy for a patient with high-grade glioblastoma
- Open Access
- 1 December 2019
- Published by Publishing House ABV Press in Russian Journal of Biotherapy
- Vol. 18 (4) , 57-64
EXPERIMENTAL IMMUNOTHERAPY MODEL OF RETINOBLASTOMA
Introduction. The main reason for enucleation of the eye when attempting organ-preserving treatment are intraocular tumors that do not respond well to chemotherapy.Purpose. The aim of the study was to find new effective and safe organ-preserving methods of treatment of intraocular refractory and recurrent retinoblastoma (RB).Materials and methods. The study included female chinchilla rabbits. The cell line of human RB was intravitreally inserted into the right eye of each animal. The left eye was a control. After obtaining a stable intraocular growth of RB and prolongation of the growth of RB, human cytotoxic lymphocytes (CTL) were intravitreally injected into the affected and control eye K1 at a concentration of 1 × 106 in 0.1 ml suspension and K2 – 5 × 106 in 0.1 ml, respectively.Results. Histological examination of the removed right eyes in animals confirmed the presence of nodal growth of malignant small-cell tumor on the border of the vascular and retinal membranes (epicenter in the choroid) on the posterior wall of the eye. There was scant lymphoid infiltration, without signs of therapeutic pathomorphosis. In the removed animal»s left eyes there is a preservation of histological structures of the eyeball, without dystrophic changes in the cells of the retina and vascular membranes. In the area of limb unit microcap lymphohistiocytic infiltration (with no elements of the tumor). In the choroid single scattered lymphocytes.Conclusion. A short period of observation of the tumor did not allow conclusions about the effectiveness of CTL, but the concentrations of CTL used in the experiment did not lead to dystrophic changes in retinal cells and the choroid of the eye, which is an important factor in overcoming the toxicity of the proposed adoptive immunotherapy. At the next stage of the experiment, in our opinion, it is necessary to study in more detail the cytotoxic effect on healthy structures of the eye and the effectiveness of CTL in a larger number of affected rabbit eyes, using their different concentrations and multiplicity of administration.
- 1 December 2019
- Published by Publishing House ABV Press in Russian Journal of Biotherapy
- Vol. 18 (4) , 57-64
Open AccessEXPERIMENTAL IMMUNOTHERAPY MODEL OF RETINOBLASTOMA
Introduction. The main reason for enucleation of the eye when attempting organ-preserving treatment are intraocular tumors that do not respond well to chemotherapy.Purpose. The aim of the study was to find new effective and safe organ-preserving methods of treatment of intraocular refractory and recurrent retinoblastoma (RB).Materials and methods. The study included female chinchilla rabbits. The cell line of human RB was intravitreally inserted into the right eye of each animal. The left eye was a control. After obtaining a stable intraocular growth of RB and prolongation of the growth of RB, human cytotoxic lymphocytes (CTL) were intravitreally injected into the affected and control eye K1 at a concentration of 1 × 106 in 0.1 ml suspension and K2 – 5 × 106 in 0.1 ml, respectively.Results. Histological examination of the removed right eyes in animals confirmed the presence of nodal growth of malignant small-cell tumor on the border of the vascular and retinal membranes (epicenter in the choroid) on the posterior wall of the eye. There was scant lymphoid infiltration, without signs of therapeutic pathomorphosis. In the removed animal»s left eyes there is a preservation of histological structures of the eyeball, without dystrophic changes in the cells of the retina and vascular membranes. In the area of limb unit microcap lymphohistiocytic infiltration (with no elements of the tumor). In the choroid single scattered lymphocytes.Conclusion. A short period of observation of the tumor did not allow conclusions about the effectiveness of CTL, but the concentrations of CTL used in the experiment did not lead to dystrophic changes in retinal cells and the choroid of the eye, which is an important factor in overcoming the toxicity of the proposed adoptive immunotherapy. At the next stage of the experiment, in our opinion, it is necessary to study in more detail the cytotoxic effect on healthy structures of the eye and the effectiveness of CTL in a larger number of affected rabbit eyes, using their different concentrations and multiplicity of administration.
- Open Access
- 20 April 2018
- Published by Paediatrician Publishers LLC in Oncopediatrics
- Vol. 5 (1) , 70-74
Immunotherapy and Immunoprofylaxis for Cancer Patients: Paradigm Shift
A concept of paradigm shift identified by Thomas Kuhn in 1962 implies a fundamental change in the basic concepts and experimental practices of a scientific discipline. A scientific revolution occurs, according to Kuhn, when scientists encounter anomalies that cannot be explained by the universally accepted paradigm within which scientific progress was made. In the beginning of the 21st century the oncologists faced with the crisis of chemotherapeutic approach to treating several neoplasms, especially in adults. The appearance of new chemotherapeutic drugs was not able to solve problem. At the same time new non-chemotherapeutic agents such anti CD20, anti GD2, protein kinase inhibitors proved their usefulness in some types of cancer. In the patients who underwent allogeneic stem cell transplants, the «graft-versus-tumor» effect was revealed to be beneficial for the recipient by eliminating residual malignant cells and to be used as a base for further immunotherapeutic modalities. There are two groups of cancer patients divided by effectiveness of chemotherapy and impact of used chemotherapeutic programs on patients’ survival. Obviously, the patients must go on to benefit from chemotherapeutic protocols, if the 5- and more years disease-free survival reaches >65–80%. But in the patients with long-term survival <5–20% with no plate on disease-free survival curve, it seems to be reasonable to hold on the conventional chemotherapy and maybe radiotherapy, and to put at the forefront a new immunotherapeutic concept for treating such types of neoplasms. In the article we propose to think over the chemotherapeutic paradigm shift and consider some immunological options for patients with cancer who failed conventional treatment.
- 20 April 2018
- Published by Paediatrician Publishers LLC in Oncopediatrics
- Vol. 5 (1) , 70-74
Open AccessImmunotherapy and Immunoprofylaxis for Cancer Patients: Paradigm Shift
A concept of paradigm shift identified by Thomas Kuhn in 1962 implies a fundamental change in the basic concepts and experimental practices of a scientific discipline. A scientific revolution occurs, according to Kuhn, when scientists encounter anomalies that cannot be explained by the universally accepted paradigm within which scientific progress was made. In the beginning of the 21st century the oncologists faced with the crisis of chemotherapeutic approach to treating several neoplasms, especially in adults. The appearance of new chemotherapeutic drugs was not able to solve problem. At the same time new non-chemotherapeutic agents such anti CD20, anti GD2, protein kinase inhibitors proved their usefulness in some types of cancer. In the patients who underwent allogeneic stem cell transplants, the «graft-versus-tumor» effect was revealed to be beneficial for the recipient by eliminating residual malignant cells and to be used as a base for further immunotherapeutic modalities. There are two groups of cancer patients divided by effectiveness of chemotherapy and impact of used chemotherapeutic programs on patients’ survival. Obviously, the patients must go on to benefit from chemotherapeutic protocols, if the 5- and more years disease-free survival reaches >65–80%. But in the patients with long-term survival <5–20% with no plate on disease-free survival curve, it seems to be reasonable to hold on the conventional chemotherapy and maybe radiotherapy, and to put at the forefront a new immunotherapeutic concept for treating such types of neoplasms. In the article we propose to think over the chemotherapeutic paradigm shift and consider some immunological options for patients with cancer who failed conventional treatment.